Identification of neoantigen-specific T cell responses in cancer patients within the Penn Medicine BioBank

Identification of neoantigen-specific T cell responses in cancer patients within the Penn Medicine BioBank
Enrolling By Invitation
18-90 years
All
Phase N/A
1 Location

Brief description of study

You are being asked to participate in this research investigation because you have expressed an interest in participating in a study to better understand how the immune cells of the body recognize and fight cancer.

Detailed description of study

The main purpose of this study is to identify immune fighting cells known as T cells that recognize proteins expressed by cancer cells. The results of this study will be used to develop new treatments for cancer patients using the body’s immune system. The study involves providing a blood sample to be used in the laboratory for immune system research at the University of Pennsylvania. Your cells will be collected and purified by members of the Vonderheide lab. Your immune cells known as white blood cells will be analyzed to determine your Human Leukocyte Antigen (HLA) type. HLA is a unique genetic marker or “fingerprint” on white blood cells that are important for how your immune system fights infections and cancer. Your white blood cells will then be used in the laboratory to study how the cells of the immune system recognize and kill cancer cells. No experimental treatments or procedures will be performed on you. These research results will not be of direct benefit to you, however, the results may provide important benefits to patients with cancer in the future. With this in mind, you are being asked to serve as a volunteer to donate white blood cells for this research study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: cancer
  • Age: Between 18 Years - 90 Years
  • Gender: All


Updated on 01 Aug 2024. Study ID: 828152
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research